A case report in the American Society of Clinical Oncology journal JCO Precision Oncology is the work of co-first authors Natalie Reizine, MD, a University of Illinois Cancer Center member, and Samantha Socco, PharmD, at the University of Illinois Chicago (UIC) College of Pharmacy, about a patient treated at UI Health for prostate cancer.
Reizine, part of the Cancer Center’s Translational Oncology research program, described the case as a success of the new Precision Oncology Tumor Board (POTB) because she utilized many multidisciplinary resources to develop a personalized treatment plan for the patient. The POTB is supported by the Cancer Center, UIC and UI Health. Socco was a Pharmacogenomics Fellow through the College of Pharmacy who worked with Reizine evaluating the patient.
Study authors, who included other researchers at UIC and the University of Chicago, described the case report as exemplifying the utility of immune checkpoint inhibitor (ICI) therapy in combination with abiraterone and prednisone in a patient with metastatic castration-resistant prostate cancer (mCRPC), who was resistant to other therapies, including a prior next-generation hormonal agent (NHA).
“These findings suggest the possibility of a synergistic mechanism of action for 2nd NHA to re-sensitize refractory mCRPC to ICI, which should be prospectively tested in biomarker-selected populations,” the study concludes.